Track the 4D Molecular Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €673.4m. The latest transaction was reported on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Bizily Scott. Every trade is openly available.
79
Insider Decl.
n/a
Thresholds
€12m
1 ops.
Buy Volume
€15m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 4D Molecular Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$29.10.
32Σ signal
Buys €12m€15m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,922 shares@ US$10.01970.4% of flowCommon StockSEC:0001193125-26-253740:0
25 of 79 declarations
Acerca de 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias génicas para enfermedades genéticas. Utiliza una plataforma tecnológica de vectores virales para diseñar tratamientos dirigidos.